-
Article
Open AccessAuthor Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
-
Article
Open Access3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
Osimertinib sensitive and resistant NSCLC NCI-H1975 clones are used to model osimertinib acquired resistance in humanized and non-humanized mice and delineate potential resistance mechanisms. No new EGFR mutat...
-
Article
Open AccessCombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
Anticancer combination therapy has been developed to increase efficacy by enhancing synergy. Patient-derived xenografts (PDXs) have emerged as reliable preclinical models to develop effective treatments in tra...
-
Article
Open AccessCombined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination therapy with MEK inhibitor selumetinib and MDM2 in...
-
Article
Open AccessAuthor Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
-
Article
Open AccessStructure-based classification predicts drug response in EGFR-mutant NSCLC
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1–3. Targeted therapies are approved for patients with ‘c...
-
Article
Open AccessComprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
Development of candidate cancer treatments is a resource-intensive process, with the research community continuing to investigate options beyond static genomic characterization. Toward this goal, we have estab...
-
Article
Author Correction: DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer
-
Article
Open AccessAuthor Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
A Correction to this paper has been published: https://doi.org/10.1038/s41588-021-00811-4.
-
Article
Open AccessmTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation
Glutathione peroxidase 4 (GPX4) utilizes glutathione (GSH) to detoxify lipid peroxidation and plays an essential role in inhibiting ferroptosis. As a selenoprotein, GPX4 protein synthesis is highly inefficient...
-
Article
Open AccessConservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts
Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical studies and therapeutic testing. It has been proposed that the mouse host affects tumor evolution during PDX engr...
-
Article
Open AccessTherapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells
The role of RNA-dependent protein kinase R (PKR) and its association with misfolded protein expression in cancer cells are unclear. Herein we report that PKR regulates misfolded protein clearance by preventing...
-
Article
Open AccessRepurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
-
Article
Open AccessPatient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
Because patient-derived xenografts (PDXs) are grown in immunodeficient mouse strains, PDXs are regarded as lacking an immune microenvironment. However, whether patients’ immune cells co-exist in PDXs remains u...
-
Article
Open AccessImmunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatment of lung cancer, the leading cause of cancer-related deaths in the United States and worldwide. Here we provide an ov...
-
Article
Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
In the version of this article originally published, information regarding several funding sources was omitted from the Acknowledgements section. The following sentences should have been included: “This work w...
-
Article
Open AccessTUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin
Expression of the TUSC2/FUS1 tumor suppressor gene in TUSC2 deficient EGFR wildtype lung cancer cells increased sensitivity to erlotinib. Microarray mRNA expression analysis of TUSC2 inducible lung cancer cell...
-
Article
Open AccessPredictive biomarkers in precision medicine and drug development against lung cancer
The molecular characterization of various cancers has shown that cancers with the same origins, histopathologic diagnoses, and clinical stages can be highly heterogeneous in their genetic and epigenetic altera...
-
Article
Open AccessElafin, an inhibitor of elastase, is a prognostic indicator in breast cancer
Elafin is an elastase-specific inhibitor with increased transcription in normal mammary epithelial cells compared to mammary carcinoma cells. In this report, we test the hypothesis that inhibition of elastase,...
-
Article
Open AccessTargeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter
The objective of this study was to evaluate the anti-tumor effects of Ad/gTRAIL (an adenoviral vector in which expression of GFP and TRAIL is driven by a human telomerase reverse transcriptase promoter, hTERT)...
